The primacy of public health considerations in defining poor quality medicines.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22162953.
- Also identified by DOI 10.1371/journal.pmed.1001139 and PMC identifier 3232210.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.
Medical subject headings
- Counterfeit Drugs
- Developing Countries
- Drug Industry
- Pharmaceutical Preparations
- Public Health